Elevage Medical Technologies
VC Fund
Elevage Medical Technologies is a VC fund focused on Medical Device and Health Care. Elevage Medical Technologies is dedicated to supporting medical device companies that can meaningfully improve health outcomes and quality of life for patients.
- Total investments:
- 11
- Last investment:
- Lead investor:
- 73%
Last updated:
For AI agents: llms.txt
Industries Elevage Medical Technologies invests in
Stages Elevage Medical Technologies invests in
Countries Elevage Medical Technologies invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Evan Melrose
|
|||
Investment Focus
Industry
- Medical Device 3 (27%)
- Health Care 2 (18%)
- Biotechnology 2 (18%)
- Medical 1 (9%)
- Neuroscience 1 (9%)
Stage
- Series B 2 (18%)
- Series D 1 (9%)
Country
- United States 2 (18%)
- Ireland 1 (9%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Evan Melrose
CEO
|
CEO | Total investments: 6 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Nervonik
|
Nervonik is a medical device company developing an opioid-free peripheral nerve stimulation (PNS) system. Nervonik is focused on advancing clinical research and achieving regulatory milestones to bring its innovative therapies to market. | $52.5M / Series B / Apr 27, 2026 | |
Imperative Care
|
Imperative Care focuses on developing a portfolio of innovative solutions to address the vast and urgent unmet needs in stroke care. It focuses on medical technology designed to expedite and improve the effectiveness of treatment, giving patients a chance for optimal recovery. | $100M / Convertible Note / Mar 17, 2026 | |
Nuclera
|
Nuclera offers a protein prototyping system to accelerate drug discovery by making proteins readily available to researchers. Nuclera's eProtein DiscoveryTM system allows scientists to rapidly produce and test proteins for drug discovery. | $12M / Series C / Jan 13, 2026 | |
Biobeat
|
Biobeat develops a wearable device for continuous, noninvasive, accurate, medical-grade monitoring of vital signs that include blood pressure, oxygen saturation, respiratory rate, heart rate, consciousness, cardiac output, stroke volume, body temperature, steps, and sweat. Its wearable device automatically uploads the recorded data to asmartphone-based application and to the cloud, where the application can monitor it remotely. Caretakers can intervene if needed, and users can receive alerts directly from the app. This provides caretakers with an important tool to assist in disease management and optimize clinical outcomes. The Biobeat system also facilitates remote monitoring of patients with a variety of medical issues. Ultimately, this solution allows patients to be treated in their homes. It can monitor stationary patients as well as those who perform outdoor activities. In 2018, Biobeat received FDA 510K clearance (K181006) for its monitoring system and partnered with DRIVe, a division of the Biomedical Advanced Research and Development Authority, to develop a wearable monitoring device that diagnoses the flu and infections before any symptoms appear. In August 2019, Biobeat received 510K FDA clearance for its patch and watch. | $50M / Series B / Dec 30, 2025 | |
Galvanize Therapeutics
|
Galvanize Therapeutics is an energy-based medical device technology that provides therapeutic products and services to deliver healthcare solutions. The company aims to become the global leader in delivering medical technology innovations that drive biological processes to treat a range of diseases, starting with treating chronic bronchitissymptoms, cardiac arrhythmias, and solid tumors.It was formed by Apple Tree Partners in 2022. | $100M / Series C / Sep 03, 2025 | |
SetPoint Medical
|
SetPoint Medical is a company that developed a device-based therapeutic approach for treating rheumatoid arthritis. The company's product, the SetPoint System, is a small, wireless implantable device that stimulates the vagus nerve to reduce inflammation. The therapy is an approach for adults with active rheumatoid arthritis who have notresponded to other treatments. | $115M / Series D / Aug 11, 2025 | |
FIRE1
|
FIRE1 and is based in Dublin, Ireland, will focus on developing novel therapeutic devices. | $120M / Series B / Jan 07, 2025 | |
|
Nuclera
|
Nuclera offers a protein prototyping system to accelerate drug discovery by making proteins readily available to researchers. Nuclera's eProtein DiscoveryTM system allows scientists to rapidly produce and test proteins for drug discovery. | $75M / Series C / Oct 15, 2024 | |
Moximed
|
Moximed Inc. is dedicated to improving the standard of care for patients with osteoarthritis, and is investigating therapies to treat a number of affected joints. The lead product, the KineSpring® Knee Implant System, is designed for patients with knee osteoarthritis. | $61M / Series D / Aug 13, 2024 | |
4Basebio
|
4Basebio focuses on life science technology, DNA manufacturing, and supply DNA products to serve the fast-growing gene therapy market. | $37.8M / Post-IPO Secondary / Jul 29, 2024 | |
| See all 11 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Elevage Medical Technologies invest in?
Elevage Medical Technologies invests primarily in Medical Device, Health Care and Biotechnology startups, most often at Series B and Series D stage. Most of the 11 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Elevage Medical Technologies?
Public channels for Elevage Medical Technologies include the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Elevage Medical Technologies?
The team at Elevage Medical Technologies includes Evan Melrose (CEO). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
